Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma

BACKGROUND: As an emerging therapy with a promising efficacy, immunotherapy has been widely used in the treatment of solid tumors and hematologic malignancies. This clinical study compares the efficacy of tislelizumab, a domestic immune checkpoint inhibitor (ICI), to that of sorafenib when used as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qijun, Dong, Yong, Pan, Yubin, Tang, Honglin, Li, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044442/
https://www.ncbi.nlm.nih.gov/pubmed/33868256
http://dx.doi.org/10.3389/fimmu.2021.634559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044442/
https://www.ncbi.nlm.nih.gov/pubmed/33868256
http://dx.doi.org/10.3389/fimmu.2021.634559

Ejemplares similares